Platelet function testing and prediction of procedural bleeding risk

Summary

The essential role of platelets in haemostasis underlies the relationship between platelet function and spontaneous or procedure-related bleeding, which has important prognostic implications. Although not routinely undertaken, platelet function testing offers the potential to tailor antiplatelet therapy for individual patients. However, uncertainties remain about how well platelet function testing may predict haemostasis and guide management of bleeding risk. Studies of aspirin, P2Y₁₂ inhibitors and other antiplatelet drugs clearly demonstrate how inhibition of platelet function increases bleeding risk. More potent antiplatelet drugs are associated with higher bleeding rates, consistent with the levels of platelet inhibition achieved by these drugs. Studies of patients treated with clopidogrel, which is associated with wide inter-individual variation in antiplatelet effect, suggest that platelet function testing may predict bleeding risk related to coronary artery bypass grafting (CABG) surgery and potentially guide the timing of surgery following discontinuation of clopidogrel. Similarly, some studies have demonstrated a relationship between clopidogrel response and bleeding in patients undergoing percutaneous coronary intervention (PCI), although other studies have not supported this. Carriage of the *17 allele of cytochrome P450 2C19, which is associated with gain of function and enhanced response to clopidogrel, seems to be associated with increased bleeding risk, although studies showing lack of apparent effect of loss-of-function alleles provide contradictory evidence. Further large studies are needed to guide best practice in the application of platelet function testing in the clinical management of patients treated with antiplatelet drugs in order to optimise individual care.

Keywords

ADP receptors - antiplatelet agents - clinical trials - antiplatelet drugs - haemostasis - platelet pharmacology

• References

• 1 Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 09: 76-91
• 2 Nurden A. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 01: 10.
• 3 Patrono C, Ciabattoni G, Patrignani P. et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1184
• 4 Schwartz KA, Schwartz DE, Ghosheh K. et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975
• 5 Ajjan RA, Standeven KF, Khanbhai M. et al. Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. Arterioscl Thromb Vasc Biol 2009; 29: 712-717.
• 6 Patrono C, Andreotti F, Arnesen H. et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
• 7 Sun JCJ, Whitlock R, Cheng J. et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
• 8 Storey RF. Biology and pharmacology of the platelet P2Y₁₂ receptor. Curr Pharm Des 2006; 12: 1255-1259.
• 9 Storey RF, Sanderson HM, White AE. et al. The central role of the P _2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
• 10 Cattaneo M. Congenital and drug-induced defects of the platelet P2Y₁₂ receptor for adenosine diphosphate. Thromb Haemost 2011; 105 (Suppl. 01) S67-74.
• 11 Andre P, Delaney SM, LaRocca T. et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
• 12 De Caterina R, Sicari R, Bernini W. et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991; 65: 504-510.
• 13 Judge HM, Buckland R, Sugidachi A. et al. Relationship between degree of P2Y₁₂ receptor blockade and inhibition of P2Y₁₂-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
• 14 Wiviott S, Braunwald E, McCabe C. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 15 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-1057.
• 16 Yusuf S, Zhao F, Mehta S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 17 Serebruany V, Rao SV, Silva MA. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.
• 18 Michelson AD, Frelinger AL, Braunwald E. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
• 19 Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18: 5379-5391.
• 20 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
• 21 Armstrong PCJ, Truss NJ, Ali FY. et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 06: 1933-1943.
• 22 Perneby C, Wallén NH, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
• 23 Henry P, Vermillet A, Boval B. et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
• 24 Deja MA, Kargul T, Domaradzki W. et al. Effects of preoperative aspirin in coronary artery bypass grafting: A double-blind, placebo-controlled, randomized trial. J Thoracic Cardiovasc Surg 2012; 144: 204-209 e3.
• 25 Fox KAA, Mehta SR, Peters R. et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8.
• 26 Gurbel PA, Bliden KP, Butler K. et al. Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients with Stable Coronary Artery Disease: The ONSET/OFFSET Study. Circulation 2009; 120: 2577-2585.
• 27 Au AG, Majumdar SR, McAlister FA. Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review. Am J Med 2012; 125: 87-99 e1.
• 28 Hamm CW, Bassand J-P, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.
• 29 Storey RF, Bliden KP, Ecob R. et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 09: 1730-1737.
• 30 Price MJ, Walder JS, Baker BA. et al. Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease: The Recovery Trial. J Am Coll Cardiol 2012; 59: 2338-2343.
• 31 Held C, Åsenblad N, Bassand JP. et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011; 57: 672-684.
• 32 Varenhorst C, Alstrom U, Scirica BM. et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60: 1623-1630.
• 33 Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011; 08: 572-579.
• 34 Chen L, Bracey AW, Radovancevic R. et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004; 128: 425-431.
• 35 Rahe-Meyer N, Winterhalter M, Boden A. et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53: 168-175.
• 36 Poston R, Gu J, Manchio J. et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardio Thoracic Surg 2005; 27: 584-591.
• 37 Kwak Y-L, Kim J-C, Choi Y-S. et al. Clopidogrel Responsiveness Regardless of the Discontinuation Date Predicts Increased Blood Loss and Transfusion Requirement After Off-Pump Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol 2010; 56: 1994-2002.
• 38 Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple Electrode Whole-Blood Aggregometry and Bleeding in Cardiac Surgery Patients Receiving Thienopyridines. Ann Thoracic Surg 2011; 91: 123-129.
• 39 Mahla E, Suarez TA, Bliden KP. et al. Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. Circulation Cardiovasc Interv 2012; 05: 261-269.
• 40 van der Linden J, Lindvall G, Sartipy U. Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Circulation. 2005 112. I-276-280.
• 41 Akowuah E, Shrivastava V, Jamnadas B. et al. A prospective randomized comparison of two strategies for the management of patients with acute coronary syndrome on clopidogrel and aspirin therapy requiring urgent coronary artery bypass graft surgery. Ann Thoracic Surg 2005; 80: 149-152.
• 42 Olenchock SA, Lee PHU, Yehoshua T. et al. Impact of Aprotinin on Adverse Clinical Outcomes and Mortality up to 12 Years in a Registry of 3,337 Patients. Ann Thoracic Surg 2008; 86: 560-567.
• 43 Ferraris VA, Saha SP, Oestreich JH. et al. 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Ann Thoracic Surg 2012; 94: 1761-1781.
• 44 Mehta SR, Yusuf S, Peters RJG. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
• 45 Becker RC, Bassand JP, Budaj A. et al. Bleeding complications with the P2Y₁₂ receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933-2944.
• 46 Mehta SR, Tanguay JF, Eikelboom JW. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
• 47 Jernberg T, Payne C, Winters K. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
• 48 Jakubowski J, Winters K, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
• 49 Storey RF, Angiolillo D, Patil S. et al. Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes: the PLATO PLATELET Substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
• 50 Price MJ, Berger PB, Teirstein PS. et al. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. J Am Med Assoc 2011; 305: 1097-1105.
• 51 Sibbing D, Schulz S, Braun S. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 08: 250-256.
• 52 Sibbing D, Koch W, Gebhard D. et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512-518.
• 53 Sibbing D, Steinhubl SR, Schulz S. et al. Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients: Initial Evidence of a Therapeutic Window. J Am Coll Cardiol 2010; 56: 317-318.
• 54 Cuisset T, Cayla G, Frere C. et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 05: 325-329.
• 55 Harmsze AM, van Werkum JW, Hackeng CM. et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
• 56 Mokhtar OA, Lemesle G, Armero S. et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010; 126: e147-e149
• 57 Patti G, Pasceri V, Vizzi V. et al. Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011; 107: 995-1000.
• 58 Cuisset T, Frere C, Quilici J. et al. Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study. JACC 2008; 01: 649-653.
• 59 Valgimigli M, Campo G, de Cesare N. et al. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study. Circulation 2009; 119: 3215-3222.
• 60 Kristensen SD, Würtz M, Grove EL. et al. Contemporary use of glycoprotein IIb/ IIIa inhibitors. Thromb Haemost 2012; 107: 215-224.
• 61 Breet N, van Werkum J, Bouman H. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
• 62 Wallentin L, James S, Storey RF. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
• 63 Cayla G, Cuisset T, Silvain J. et al. Prasugrel Monitoring and Bleeding in Real World Patients. Am J Cardiol 2013; 111: 38-44.
• 64 Price MJ, Murray SS, Angiolillo DJ. et al. Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention: The GIFT (Genotype Information and Functional Testing) Study. J Am Coll Cardiol 2012; 59: 1928-1937.